CORRESPONDENCE
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). This rearrangement results in the disruption of the myosin heavy chain (MYH) gene at 16p13 and the core binding factor ␤ (CBF␤) gene at 16q22. 2 Until now, 10 different CBF␤-MYH11 transcripts have been reported [3] [4] [5] [6] (A to J), but the frequency of each transcript is variable: 85% for the A type, 5% for each of the D and E types, other rearrangements being rare. Recently, a standardized RT-PCR technique, considered to be able to identify all CBF␤-MYH11 transcripts, has been reported. 6 From 1993 to 2001, we analyzed 40 cases of inv(16) by RT-PCR. All 40 cases showed CBF␤-MYH11 rearrangement, which was A type in 36 cases and D type in two cases. In this report, we present the remaining two cases of CBF␤-MYH11 rearrangement, with I type fusion transcript, corresponding to a breakpoint nt 399 (exon 4) of the CBF␤ gene and at nt 2134 (exon 13) of the MYH11gene. To date, to our knowledge, only one case of I type transcript had been reported. In both patients, inv(16) was confirmed by FISH using CBF␤ dualcolor probes (Vysis, Downers Grove, IL, USA) (Figure 1d, h ). Preliminary study by RT-PCR using the technique described and recommended by the Biomed-1 concerted action 6 was negative for the Because a new CBF␤-MYH11 transcript (I type) had been reported by Dissing et al 7 in a case of therapy-related AML with inv(16), we designed a new reverse primer on exon 13 of MYH11 gene (MYH13: 5′ gTT-CgT-TTC-gCT-CgT-CTT-CCA-gT-3′) in order to use the same forward primer (CBF A located on exon 4 of CBF␤) and the otherwise classical RT-PCR protocol recommended by the Biomed-1 concerted action. 6 In both patients we obtained, using CBFA and MYH13 primers, a specific PCR product of 169 bp (Figure 2a) which after sequencing showed a breakpoint at nt 399 (exon 4) of the CBF␤ gene and at nt 2134 (exon 13) of MYH11 gene (Figure 2b) , as found by Dissing et al 7 in the I form transcript. Interestingly, using these primers, amplification of the A type tran- script found in Me-1 cell line and in several patients was better than with the set of primers recommended by the Biomed-1 (data not shown).
To our knowledge, no case of I type transcript has been reported since the first description of one case by Dissing et al. 7 Our patient No. 1 had therapy-related AML, like the patient described by Dissing et al 7 who had also received chemotherapy (with 5FU, mitoxantrone and cyclophosphamide) for breast cancer.
In our patient No. 2, in contrast, no previous therapy or toxic exposure was found, suggesting that I type transcript is not absolutely linked to prior therapy.
Whereas the patient reported by Dissing et al 7 had typical M4Eo morphological features, our two cases had atypical cytological findings: in case No. 1, no abnormal eosinophils were observed in the bone marrow, dysgranulopoiesis was prominent and FAB classification was M2 AML. In case No. 2, FAB classification was also M2 AML with major dysgranulopoiesis and dyserythropoiesis and large numbers of Auer rods in blast cells but also in mature granulocytes, as seen in M2 AML with t(8;21). However, this patient also had abnormal eosinophils, and no AML1-ETO transcript was detected (data not shown).
In conclusion, this work reports, to our knowledge, the second and third cases of I type CBF␤-MYH11 transcript in AML. Our findings suggest that this transcript may be prevalent in therapy related AML with inv(16). MYH13 primer should be used in addition to primers 
